Robert Tjian

Title: The Innovations of Robert Tjian

Introduction

Robert Tjian is a prominent inventor based in Berkeley, CA (US). He has made significant contributions to the field of molecular biology, particularly in the area of transcription factors. With a total of 3 patents, Tjian's work has had a profound impact on the development of pharmaceuticals and biopharmaceuticals.

Latest Patents

One of Tjian's latest patents focuses on a cell-type specific transcription factor. This invention provides methods and compositions relating to human tata-binding protein associated factor 105 (hTAF.sub.II 105) and related nucleic acids. The proteins can be produced recombinantly from transformed host cells using the disclosed hTAF.sub.II 105 encoding nucleic acids or purified from human cells. Additionally, the invention includes isolated hTAF.sub.II 105 hybridization probes and primers capable of specifically hybridizing with the hTAF.sub.II 105 gene. It also covers hTAF.sub.II 105-specific binding agents, such as specific antibodies, and methods of making and using these compositions in diagnosis, therapy, and the biopharmaceutical industry. Another patent involves TATA-binding protein associated factors, which are nuclear proteins involved in RNA polymerase I, II, and III transcription. The disclosed methods and compositions are useful in developing pharmaceuticals, diagnosis, and therapy.

Career Highlights

Robert Tjian has had a distinguished career at the University of California, where he has been instrumental in advancing research in molecular biology. His innovative work has not only led to numerous patents but has also paved the way for new therapeutic approaches in medicine.

Collaborations

Throughout his career, Tjian has collaborated with notable scientists, including Lucio Comai and Timothy Hoey. These collaborations have further enriched his research and contributed to the scientific community.

Conclusion

Robert Tjian's contributions to the field of molecular biology through his patents and research have significantly advanced our understanding of transcription factors. His work continues to influence the development of new therapies and diagnostics in the biopharmaceutical industry.